Immunoassay CDMO demand in USA is projected to grow from USD 4.20 billion in 2025 to USD 10.30 billion by 2036, at a CAGR of 8.5%. Manufacturing and Production will dominate with a 53.0% services share, while Diagnostic Companies will dominate with a 48.2% end user share.